Anti-integrin αvβ6 Autoantibodies are Increased in Primary Sclerosing Cholangitis Patients With Concomitant Inflammatory Bowel Disease and Correlate With Liver Disease Severity.

Autor:	Bloemen H; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Livanos AE; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: alexandra.livanos@mountsinai.org., Martins A; Schiff Center for Liver Diseases, University of Miami Leonard M. Miller School of Medicine, Miami, Florida., Dean R; Division of Gastroenterology and Hepatology, University of California Davis School of Medicine, Sacramento, California., Bravo AC; Division of Gastroenterology, Hospital Beatriz Ângelo, Loures, Portugal., Bourgonje AR; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Tankelevich M; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Herb J; The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, New York., Cho J; The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, New York., Santos AA; Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal., Rodrigues CMP; Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal., Petralia F; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York., Colombel JF; Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York., Bowlus CL; Division of Gastroenterology and Hepatology, University of California Davis School of Medicine, Sacramento, California., Schiano T; Recanati/Miller Transplantation Institute, Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York., Torres J; Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York; Division of Gastroenterology, Hospital Beatriz Ângelo, Loures, Portugal; Faculty of Medicine, Universidade de Lisboa, Lisbon, Portugal; Division of Gastroenterology, Hospital da Luz, Lisbon, Portugal., Levy C; Schiff Center for Liver Diseases, University of Miami Leonard M. Miller School of Medicine, Miami, Florida; Division of Digestive Health and Liver Diseases, University of Miami Miller School of Medicine, Miami, Florida. Electronic address: clevy@med.miami.edu., Mehandru S; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: saurabh.mehandru@mssm.edu.
Jazyk:	angličtina
Zdroj:	Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association [Clin Gastroenterol Hepatol] 2024 Oct 25. Date of Electronic Publication: 2024 Oct 25.
DOI:	10.1016/j.cgh.2024.10.005
Abstrakt:	Background & Aims: Anti-integrin αvβ6 autoantibodies (anti-αvβ6) are found in more than 50% of individuals with ulcerative colitis (UC). We aimed to determine the prevalence of anti-αvβ6 in patients with primary sclerosing cholangitis (PSC) and their association with liver disease severity. Methods: Four cohorts of pre-liver transplant patients with PSC were recruited. Patients with inflammatory bowel disease (IBD) and healthy controls (HCs) served as comparators. Total IgG and anti-αvβ6 levels were measured using enzyme-linked immunosorbent assay. Olink inflammation panel was run on a subset of samples. Multivariable linear regression analysis was performed to assess the association between anti-αvβ6 and indices of liver disease severity. Results: A total of 137 patients with PSC (including 76 with PSC-UC, 33 with PSC-Crohn's disease (CD), and 28 with PSC alone) and 160 controls (including 91 with IBD and 69 HCs) were enrolled. Anti-αvβ6 levels were significantly higher in PSC-UC and PSC-CD compared with PSC alone (P < .0001 and P < .003) and HCs (P < .0001 and P < .0001). However, anti-αvβ6 levels in PSC alone were not increased compared with HCs. In patients with PSC-IBD, anti-αvβ6 levels correlated with markers of liver disease severity, including alkaline phosphatase level (r = 0.32; P = .004), the revised Mayo PSC risk score (r = 0.25; P = .02), and liver stiffness measurement (r = 0.43; P = .008) after adjusting for age, gender, race/ethnicity, and IBD subtype. Additionally, anti-αvβ6 levels were associated with markers of systemic inflammation and tissue remodeling. Conclusion: Anti-αvβ6 autoantibodies identify a subset of patients with PSC with concomitant IBD. (Copyright © 2024 AGA Institute. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu